Conclusion
This retrospective cohort analysis advances that CF-specific variability
is likely to cause the current tobramycin dosing regimen to be
sub-optimal. Rigorous identification of additional factors is needed to
account for this variability. The evaluation of regimens through their
predictive attainment of PK/PD targets remains the fastest way to
evaluate a dosing strategy and its factors. Clinically history of APEs
is predictive of clinical outcomes. Further population PK models must be
developed in our population to optimize current treatment thus
increasing clinical efficacy.
References
1. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, et
al. Pulmonary exacerbations in cystic fibrosis. Pediatric pulmonology.
2004;37(5):400-6.
2. Waters V, Stanojevic S, Atenafu EG, Lu A, Yau Y, Tullis E, et al.
Effect of pulmonary exacerbations on long-term lung function decline in
cystic fibrosis. Eur Respir J. 2012;40(1):61-6.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC.
Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol.
2001;153(4):345-52.
4. Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA,
et al. A contemporary survival analysis of individuals with cystic
fibrosis: a cohort study. Eur Respir J. 2015;45(3):670-9.
5. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn
RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary
exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-8.
6. Prescott WA, Jr. A survey of extended-interval aminoglycoside dosing
practices in United States adult cystic fibrosis programs. Respiratory
care. 2014;59(9):1353-9.
7. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, et
al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis
pulmonary exacerbations: VI. Executive summary. Pediatric pulmonology.
2013;48(6):525-37.
8. Munzenberger PJ, Commissaris RL, Massoud N, Hsu MC. Variability of
tobramycin pharmacokinetics in cystic fibrosis. Pediatr Infect Dis J.
1987;6(8):739-43.
9. Vandenbussche HL, Homnick DN. Evaluation of serum concentrations
achieved with an empiric once-daily tobramycin dosage regimen in
children and adults with cystic fibrosis. The journal of pediatric
pharmacology and therapeutics : JPPT : the official journal of PPAG.
2012;17(1):67-77.
10. Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K. Construct
and longitudinal validity of a modified Huang clinical scoring system in
adult cystic fibrosis patients. Eur Respir J. 1999;13(3):552-9.
11. Varvel JR, Donoho DL, Shafer SL. Measuring the predictive
performance of computer-controlled infusion pumps. Journal of
pharmacokinetics and biopharmaceutics. 1992;20(1):63-94.
12. Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott
DJ, et al. Towards precision dosing of vancomycin: a systematic
evaluation of pharmacometric models for Bayesian forecasting. Clinical
microbiology and infection : the official publication of the European
Society of Clinical Microbiology and Infectious Diseases.
2019;25(10):1286.e1-.e7.
13. Hara M, Masui K, Eleveld DJ, Struys M, Uchida O. Predictive
performance of eleven pharmacokinetic models for propofol infusion in
children for long-duration anaesthesia. British journal of anaesthesia.
2017;118(3):415-23.
14. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute
kidney injury: a KDIGO summary (Part 1). Critical care (London,
England). 2013;17(1):204.
15. Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal
support for acute kidney injury: a KDIGO summary (Part 2). Critical care
(London, England). 2013;17(1):205.
16. Alghanem S, Paterson I, Touw DJ, Thomson AH. Influence of multiple
courses of therapy on aminoglycoside clearance in adult patients with
cystic fibrosis. The Journal of antimicrobial chemotherapy.
2013;68(6):1338-47.
17. Crass RL, Pai MP. Optimizing Estimated Glomerular Filtration Rate to
Support Adult to Pediatric Pharmacokinetic Bridging Studies in Patients
with Cystic Fibrosis. Clinical pharmacokinetics. 2019;58(10):1323-32.
18. Alghanem SS, Touw DJ, Thomson AH. Pharmacokinetic/pharmacodynamic
analysis of weight- and height-scaled tobramycin dosage regimens for
patients with cystic fibrosis. The Journal of antimicrobial
chemotherapy. 2019;74(8):2311-7.
19. Hong LT, Liou TG, Deka R, King JB, Stevens V, Young DC.
Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of
Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.
Chest. 2018;154(5):1108-14.
20. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, et
al. A survey of the utilization of anti-pseudomonal beta-lactam therapy
in cystic fibrosis patients. Pediatric pulmonology. 2011;46(10):987-90.
21. Fischer DR, Namanny H, Zobell JT. Follow-up survey of the
utilization of anti-pseudomonal beta-lactam antibiotics at U.S. cystic
fibrosis centers. Pediatric pulmonology. 2016;51(7):668-9.
22. Prescott WA, Jr., Nagel JL. Extended-interval once-daily dosing of
aminoglycosides in adult and pediatric patients with cystic fibrosis.
Pharmacotherapy. 2010;30(1):95-108.
23. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D,
et al. Once versus three-times daily regimens of tobramycin treatment
for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a
randomised controlled trial. Lancet (London, England).
2005;365(9459):573-8.
24. Francis J. Gilchrist KJC, A. Kevin Webb, Rowland J. Bright-Thomas,
Andrew M. Jones. Possible compromises for the dosing of IV tobramycin in
cystic fibrosis. The Pharmaceutical Journal. 2013;290:89.
25. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and
acute toxicity of repeated high-dose tobramycin treatment in cystic
fibrosis. Antimicrob Agents Chemother. 1987;31(4):594-9.
26. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic
fibrosis. Pharm World Sci. 1998;20(4):149-60.
27. Spino M. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev
Allergy. 1991;9(1-2):169-210.
28. Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 1.
Pediatric pulmonology. 2019;54(8):1117-28.
29. Savant AP, McColley SA. Cystic fibrosis year in review 2018, part 2.
Pediatric pulmonology. 2019;54(8):1129-40.
30. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety
of meropenem and tobramycin vs ceftazidime and tobramycin in the
treatment of acute pulmonary exacerbations in patients with cystic
fibrosis. Chest. 2005;128(4):2336-46.
31. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N,
Borneff-Lipp M, et al. Antibiotic-resistant obligate anaerobes during
exacerbations of cystic fibrosis patients. Clinical microbiology and
infection : the official publication of the European Society of Clinical
Microbiology and Infectious Diseases. 2009;15(5):454-60.
32. CFC. The Canadian Cystic Fibrosis Registry: 2017 Annual Data Report.
2017.
33. Rutter WC, Burgess DR, Burgess DS. Increasing Incidence of Multidrug
Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates. Microb
Drug Resist. 2017;23(1):51-5.
34. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH. Pulmonary
exacerbations are associated with subsequent FEV1 decline in both adults
and children with cystic fibrosis. Pediatric pulmonology.
2011;46(4):393-400.
35. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott
RW. Impact of recent pulmonary exacerbations on quality of life in
patients with cystic fibrosis. Chest. 2002;121(1):64-72.
36. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis.
The Cochrane database of systematic reviews. 2003(3):Cd001912.
37. Smyth AR, Rosenfeld M. Prophylactic anti‐staphylococcal antibiotics
for cystic fibrosis. Cochrane Database of Systematic Reviews. 2017(4).
38. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the
rationale that bacterial eradication in respiratory tract infection is
an important aim of antimicrobial therapy. The Journal of antimicrobial
chemotherapy. 2001;47(2):129-40.